A5013224190- Multiple Sclerosis Research Studies
- SARS-CoV-2 and COVID-19 Research
- Peripheral Neuropathies and Disorders
- Sphingolipid Metabolism and Signaling
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- Autoimmune Neurological Disorders and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Herpesvirus Infections and Treatments
- Neurogenesis and neuroplasticity mechanisms
- Systemic Lupus Erythematosus Research
- Viral gastroenteritis research and epidemiology
- Listeria monocytogenes in Food Safety
- Radiation Effects and Dosimetry
Isfahan University of Medical Sciences
2020-2022
Alzahra Medical and Education Center
2021
Alzahra University
2021
Universal Scientific Education and Research Network
2021
COVID-19 is speculated to increase the likelihood of relapsing-remitting multiple sclerosis (RRMS) exacerbation.To investigate association between contraction and incidence acute MS attacks in RRMS patients six months post-infection.This retrospective cohort study compares risk relapse with (n=56) without (n=69). Incidence was recorded for six-month following COVID-19. exacerbation compared (the independent control group) same prior pandemic.A lower rate observed that contracted than who did...
Various studies indicated blunted humoral responses to COVID-19 mRNA and viral vector vaccines among people with multiple sclerosis (pwMS) on sphingosine 1-phosphate receptor (S1PR) modulators anti-CD20 therapies (aCD20); however, limited evidence was found regarding SARS-CoV-2 serology after inactivated virus vaccination.
Background: Various studies indicated blunted humoral responses to COVID-19 mRNA and viral vector vaccines among people with multiple sclerosis (pwMS) on sphingosine 1-phosphate receptor (S1PR) modulators anti-CD20 therapies (aCD20); however, no study was found assessing SARS-CoV-2 serology after inactivated virus vaccination. Objective: To provide evidence regarding response vaccination pwMS disease-modifying (DMTs). Methods: A cohort carried out in Isfahan, Iran, enrolling DMT-exposed...
Abstract Background and Purpose: Fingolimod, a sphingosine-1-phosphate receptor modulator, is drug for treatment multiple sclerosis. Since S1P receptors are highly expressed in various tissues, it could cause broad range of side effects. We investigated the effect fingolimod on appetite body weight. Methods: This study evaluated 218 MS patients Isfahan center (IMSC) from 2016 to 2020. They were requested fill out relevant questionnaires this study, Proper examinations performed with history...